Two studies found that Genentech’s cancer drug Avastin failed to prolong life on patients, but kept their disease from worsening for a time, the Washington Post reports.
The two studies released Thursday showed the drug could slow the growth of ovarian cancer when added to chemotherapy, news that was welcomed by patient advocates, who point to the lack of new treatments for the disease.
With the mixed results, though, Genentech said it was unlikely at this time to seek Food and Drug Administration approval of Avastin for ovarian cancer.
